Chardan Capital Issues Optimistic Estimate for OCUL Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Equities research analysts at Chardan Capital raised their FY2025 earnings per share estimates for shares of Ocular Therapeutix in a research note issued to investors on Wednesday, November 5th. Chardan Capital analyst D. Gataulin now expects that the biopharmaceutical company will post earnings per share of ($1.43) for the year, up from their prior estimate of ($1.45). Chardan Capital has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.98) per share. Chardan Capital also issued estimates for Ocular Therapeutix’s FY2026 earnings at ($1.22) EPS.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.02. Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%.The business had revenue of $14.54 million for the quarter, compared to analyst estimates of $14.57 million.

Several other equities research analysts also recently commented on the company. Zacks Research upgraded Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a report on Thursday, October 2nd. Royal Bank Of Canada restated an “outperform” rating on shares of Ocular Therapeutix in a research note on Wednesday, November 5th. Piper Sandler boosted their price objective on shares of Ocular Therapeutix from $21.00 to $31.00 and gave the stock an “overweight” rating in a report on Friday, October 3rd. Scotiabank reduced their price target on Ocular Therapeutix from $22.00 to $20.00 and set a “sector outperform” rating for the company in a report on Wednesday, August 6th. Finally, TD Cowen raised their price objective on Ocular Therapeutix from $14.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.33.

Ocular Therapeutix Stock Down 0.2%

Shares of NASDAQ OCUL opened at $10.83 on Monday. The stock has a fifty day moving average price of $11.93 and a 200 day moving average price of $10.56. The company has a market cap of $2.31 billion, a P/E ratio of -8.46 and a beta of 1.53. Ocular Therapeutix has a 12-month low of $5.78 and a 12-month high of $13.85. The company has a current ratio of 10.10, a quick ratio of 10.02 and a debt-to-equity ratio of 0.23.

Insider Buying and Selling at Ocular Therapeutix

In other Ocular Therapeutix news, insider Peter Kaiser sold 9,653 shares of the business’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $11.03, for a total transaction of $106,472.59. Following the completion of the transaction, the insider owned 194,440 shares in the company, valued at approximately $2,144,673.20. The trade was a 4.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Todd Anderman sold 11,132 shares of the firm’s stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $12.34, for a total transaction of $137,368.88. Following the transaction, the insider directly owned 87,568 shares in the company, valued at approximately $1,080,589.12. The trade was a 11.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 61,806 shares of company stock valued at $727,648 over the last three months. 2.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Graypoint LLC bought a new position in Ocular Therapeutix during the 1st quarter valued at $148,000. XTX Topco Ltd raised its position in Ocular Therapeutix by 95.0% in the first quarter. XTX Topco Ltd now owns 22,605 shares of the biopharmaceutical company’s stock worth $166,000 after acquiring an additional 11,012 shares in the last quarter. Banco Santander S.A. lifted its holdings in Ocular Therapeutix by 21.8% in the 1st quarter. Banco Santander S.A. now owns 184,048 shares of the biopharmaceutical company’s stock valued at $1,349,000 after acquiring an additional 32,941 shares during the last quarter. Nuveen LLC bought a new position in shares of Ocular Therapeutix during the 1st quarter valued at about $3,035,000. Finally, Algert Global LLC acquired a new position in shares of Ocular Therapeutix in the 1st quarter worth approximately $213,000. 59.21% of the stock is currently owned by institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.